ORPHA:886
Usher syndrome
Also known as: Retinitis pigmentosa-deafness syndrome · Retinitis pigmentosa-hearing loss syndrome · USH
Publications
5,396
Trials
15
Interventional, condition-specific
Researchers
1,423
Distinct authors in sample
Gene link
—
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare ciliopathy characterized by or childhood onset sensorineural hearing loss (HL) and retinitis pigmentosa (RP) that occurs in a second step with a night blindness and a vision loss and, in some cases, vestibular dysfunction.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019501
- MeSH:D052245
- NCIT:C85217
Additional Mondo synonyms (2)
Usher's syndrome · ush
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
5,396 matched papers (2,997 in last 10 years) Source
- Phenotype characterisedPresent
150 HPO annotations (e.g. Progressive visual loss; Blindness; Nyctalopia) Source
- Animal modelPresent
62 genotype models (Danio rerio, Mus musculus) Source
- Orphan designationPartial
1 EMA designation (none yet with FDA orphan-indication approval) — e.g. mixture of two adeno-associated viral vectors serotype 8 containing the 5'-half sequence of human MYO7A gene and the 3'-half sequence of human MYO7A gene Source
- Interventional trialPresent
15 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
150
Associated phenotypes · MONDO:0019501
- Progressive visual loss
- Blindness
- Nyctalopia
- Sensorineural hearing impairment
- Visual impairment
Showing 5 of 150 — open Monarch for the full list.
Animal models (Monarch / Alliance)
62
Model associations linked to this Mondo ID
- clrn1cwr1001/cwr1001·ZFIN:ZDB-FISH-161111-1·Danio rerio
- Ush1gjs/Ush1gjs [background:] B6.A-Ush1gjs/J·MGI:3581211·Mus musculus
- Ush1ctm1Xzl/Ush1ctm1Xzl [background:] involves: 129S1/Sv * 129X1/SvJ·MGI:5751490·Mus musculus
- Cdh23v-4J/Cdh23v-4J [background:] involves: C57BLKS/J·MGI:5050420·Mus musculus
- Adgrv1tm1Msat/Adgrv1tm1Msat [background:] involves: 129P2/OlaHsd * C57BL/6J·MGI:3527887·Mus musculus
- Myo7apolka/Myo7apolka [background:] involves: C57BL/6J·MGI:3709041·Mus musculus
- Cdh23v-bus/Cdh23v-bus [background:] involves: KYF/MsIdr·MGI:5140950·Mus musculus
- Cdh23v-ngt/Cdh23v-ngt [background:] involves: ICR * MSM·MGI:3714862·Mus musculus
- Myo7a816SB/Myo7a816SB [background:] involves: BALB/cRl·MGI:3587760·Mus musculus
- ush1cfh293/fh293·ZFIN:ZDB-FISH-150901-13175·Danio rerio
- clrn1cwr1003/cwr1003·ZFIN:ZDB-FISH-161111-3·Danio rerio
- Clrn1tm1.1Kuna/Clrn1tm1.1Kuna Tg(Atoh1-Clrn1)#Kuna/0 [background:] involves: C57BL/6J·MGI:6156835·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- EMA mixture of two adeno-associated viral vectors serotype 8 containing the 5'-half sequence of human MYO7A gene and the 3'-half sequence of human MYO7A geneTreatment of Usher syndrome · 04/07/2014 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
1
Drugs / clinical candidates · MONDO_0019501
- CILIARY NEUROTROPHIC FACTOR·phase 2
CTD chemicals (MyDisease.info)
1 associated chemical · 3 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- 5-O-(5-amino-5-deoxyribofuranosyl)-1N-(4-amino-2-hydroxybutanoyl)paromamine · therapeutic
Pathways: Signal Transduction; Visual phototransduction; The canonical retinoid cycle in rods (twilight vision)
Literature
Is anyone studying this?
5,396
5,396 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
5,396 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,997 in the last 10 years · low confidence
Phrase hits: 5,396 · MeSH hits: 0
Who's working on it?
1,423
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Stingl K7 papers · 2026
Department for Ophthalmology, University Eye Clinic, Eberhard Karls University of Tübingen, 72076, Tübingen, Germany.
Papers in Europe PMC - 02van Wijk E7 papers · 2026
Department of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 03de Vrieze E6 papers · 2026
Department of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 04Kohl S5 papers · 2026
Department for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University of Tübingen, 72076, Tübingen, Germany.
Papers in Europe PMC - 05Nagel-Wolfrum K5 papers · 2026
Institute of Molecular Physiology, Molecular Cell Biology, Johannes Gutenberg University Mainz, Mainz, Germany.
Papers in Europe PMC - 06Wolfrum U5 papers · 2026
Institute of Molecular Physiology, Molecular Cell Biology, Johannes Gutenberg University Mainz, Mainz, Germany. wolfrum@uni-mainz.de.
Papers in Europe PMC - 07Barakat A4 papers · 2026
Genomics and Human Genetics Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco.
Papers in Europe PMC - 08Charoute H4 papers · 2026
Genomic Sequencing Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco.
Papers in Europe PMC - 09Cremers FPM4 papers · 2025
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Papers in Europe PMC - 10Kremer H4 papers · 2026
Department of Otorhinolaryngology, Radboud University Medical Center, Nijmegen 6525 GA, The Netherlands.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
15
interventional trials for this specific condition
15 interventional trials matched this specific condition name; 5 currently recruiting in our sample.
Data as of 11 September 2026
15 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94th percentile).
low confidence · 94th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
15 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06592131·NOT YET RECRUITING·BF844 Safety and Pharmacokinetic Study in Healthy Volunteers
Not reviewed·Conditions: Usher Syndrome Type 3·Matched via name phrase
- NCT07710196·NOT YET RECRUITING·A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Not reviewed·Conditions: Retinitis Pigmentosa (RP) · Usher Syndrome·Matched via name phrase
- NCT06789445·RECRUITING·A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Not reviewed·Conditions: Primary Photoreceptor Disease · Retinitis Pigmentosa (RP) · Usher Syndrome · Inherited Retinal Disease (IRD)·Matched via name phrase
- NCT07290530·NOT YET RECRUITING·24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Not reviewed·Conditions: Retinitis Pigmentosa (RP) · Usher Syndrome·Matched via name phrase
- NCT06591793·RECRUITING·Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Not reviewed·Conditions: Usher Syndrome, Type 1B·Matched via name phrase
Observational and natural-history studies
14 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07548944·RECRUITING·Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Not reviewed·Conditions: Retinitis Pigmentosa (RP) · Usher Syndrome · Cone Rod Dystrophy·Matched via name phrase
- NCT02435940·RECRUITING·Inherited Retinal Degenerative Disease Registry
Not reviewed·Conditions: Eye Diseases Hereditary · Retinal Disease · Achromatopsia · Bardet-Biedl Syndrome·Matched via name phrase
- NCT04665726·RECRUITING·Natural History Study of Usher Syndrome ( Light4Deaf )
Not reviewed·Conditions: Usher Syndromes·Matched via name phrase
- NCT07278843·RECRUITING·Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A
Not reviewed·Conditions: Usher Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 9 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (9)
- ctis·2024-518489-29-00·Expired·A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Participants with Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa
skipped — LLM skipped (--skip-llm)
- ctis·2024-513500-34-00·Expired·An open-label study to determine the long-term safety, tolerability and biological activity of SAR421869 in patients with Usher syndrome Type 1B
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17719284·No longer recruiting·PREDICT Kidney clinical feasibility study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11774433·No longer recruiting·PANACHE: A Pilot randomised trial comparing two forms of Absorbable versus Non-Absorbable sutures for Carpal tunnel Hand surgEry
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12637839·No longer recruiting·Cell therapy for acute liver injury trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN40292537·No longer recruiting·Early Pandemic Evaluation and Enhanced Surveillance of the coronavirus COVID-19 (EAVE II)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18035454·No longer recruiting·A2B – a study investigating the effect of different types of sedation on the length of time critically ill patients require ventilation in intensive care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65230311·No longer recruiting·Efficacy and safety of growth hormone treatment in short children born small for gestational age; effects of growth hormone levels on growth, insulin sensitivity and body composition
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96883876·No longer recruiting·Growth hormone treatment of children after IntraUterine Growth Retardation: IUGR-2 study
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Usher syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Usher syndrome" OR "Retinitis pigmentosa-deafness syndrome" OR "Retinitis pigmentosa-hearing loss syndrome" OR "Usher's syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Usher syndrome" OR "Retinitis pigmentosa-deafness syndrome" OR "Retinitis pigmentosa-hearing loss syndrome" OR "Usher's syndrome"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 15 interventional · 14 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: USH
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:45:24.812Z
